ANI Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US00182C1036

Introduction

This page provides a comprehensive analysis of the known insider trading history of Patrick D Walsh. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Patrick D Walsh has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ANIP / ANI Pharmaceuticals, Inc. Director 70,048
US:LNDC / Landec Corp. Director 7,059
US:CDMO / Avid Bioservices, Inc. Director 2,379
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Patrick D Walsh. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ANIP / ANI Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ANIP / ANI Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-03-21 ANIP Walsh Patrick D 5,000 27.7588 5,000 27.7588 138,794 323 45.7200 89,806 64.70
2021-03-15 ANIP Walsh Patrick D 4,000 32.8888 4,000 32.8888 131,555
2020-11-09 ANIP Walsh Patrick D 5,000 25.9600 5,000 25.9600 129,800
2020-08-10 ANIP Walsh Patrick D 3,000 30.4000 3,000 30.4000 91,200
2020-08-10 ANIP Walsh Patrick D 4,000 30.9800 4,000 30.9800 123,920
2020-08-10 ANIP Walsh Patrick D 3,000 30.8900 3,000 30.8900 92,670

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ANIP / ANI Pharmaceuticals, Inc. Insider Trades
Insider Sales ANIP / ANI Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ANIP / ANI Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-08-15 ANIP Walsh Patrick D 9,000 89.0500 9,000 89.0500 801,450 0 87.4700 -14,220 -1.77

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ANIP / ANI Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Patrick D Walsh as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-08-18 2025-08-15 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
S - Sale -9,000 70,048 -11.39 89.05 -801,450 6,237,774
2025-05-27 2025-05-22 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
A - Award 4,336 79,048 5.80
2024-05-23 2024-05-21 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
A - Award 4,410 74,712 6.27
2023-05-24 2023-05-23 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
A - Award 6,865 70,302 10.82
2022-04-29 2022-04-27 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
A - Award 10,049 63,437 18.82
2022-03-22 2022-03-21 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
P - Purchase 5,000 53,388 10.33 27.76 138,794 1,481,987
2021-06-08 2021-06-04 4 LNDC LANDEC CORP \CA\
Restricted Stock Unit
A - Award 7,059 7,059
2021-04-22 2021-04-20 4 LNDC LANDEC CORP \CA\
Common Stock
P - Purchase 10,000 40,000 33.33 11.26 112,600 450,400
2021-03-25 2021-03-23 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
A - Award 9,292 48,388 23.77
2021-03-17 2021-03-15 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
P - Purchase 4,000 39,096 11.40 32.89 131,555 1,285,821
2020-12-16 2020-12-14 4 CDMO Avid Bioservices, Inc.
Restricted Stock Units
A - Award 2,379 2,379
2020-12-16 2020-12-14 4 CDMO Avid Bioservices, Inc.
Stock Option (right to buy)
A - Award 10,030 124,305 8.78
2020-11-12 2020-11-09 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
P - Purchase 5,000 35,096 16.61 25.96 129,800 911,092
2020-10-21 3/A LNDC LANDEC CORP \CA\
Common Stock
30,000
2020-10-16 2020-10-14 4 LNDC LANDEC CORP \CA\
Restricted Stock Unit
A - Award 5,398 5,398
2020-10-15 3 LNDC LANDEC CORP \CA\
No Security beneficially owned
0
2020-08-12 2020-08-10 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
P - Purchase 3,000 30,096 11.07 30.89 92,670 929,665
2020-08-12 2020-08-10 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
P - Purchase 4,000 27,096 17.32 30.98 123,920 839,434
2020-08-12 2020-08-10 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
P - Purchase 3,000 23,096 14.93 30.40 91,200 702,118
2020-05-13 2020-05-11 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
A - Award 7,050 20,096 54.04
2020-04-14 2020-04-10 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
A - Award 9,255 13,046 244.13
2020-03-25 2020-03-23 4 CDMO Avid Bioservices, Inc.
Common Stock, $0.001 par value
P - Purchase 30,000 30,000 3.22 96,600 96,600
2020-01-13 2020-01-09 4 CDMO Avid Bioservices, Inc.
Stock Option (right to buy)
A - Award 19,675 114,275 20.80
2019-04-01 2019-03-28 4 ANIP ANI PHARMACEUTICALS INC
Stock Options
A - Award 2,409 2,409
2019-04-01 2019-03-28 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
A - Award 1,991 3,791 110.61
2018-12-18 2018-12-14 4 CDMO Avid Bioservices, Inc.
Stock Option (right to buy)
A - Award 19,600 94,600 26.13
2018-06-08 2018-06-06 4 ANIP ANI PHARMACEUTICALS INC
Stock Options
A - Award 2,225 2,225
2018-06-08 2018-06-06 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
A - Award 1,800 1,800
2018-05-24 3 ANIP ANI PHARMACEUTICALS INC
Common Stock
0
2017-10-24 2017-10-20 4 PPHM PEREGRINE PHARMACEUTICALS INC
Stock Options (right to buy)
A - Award 75,000 75,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)